UK markets closed
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • FTSE 250

    20,372.52
    +123.78 (+0.61%)
     
  • AIM

    968.25
    +10.25 (+1.07%)
     
  • GBP/EUR

    1.1764
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • BTC-GBP

    22,874.41
    -126.62 (-0.55%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • DOW

    33,212.96
    +575.77 (+1.76%)
     
  • CRUDE OIL

    115.07
    +0.98 (+0.86%)
     
  • GOLD FUTURES

    1,850.60
    +3.00 (+0.16%)
     
  • NIKKEI 225

    26,781.68
    +176.84 (+0.66%)
     
  • HANG SENG

    20,697.36
    +581.16 (+2.89%)
     
  • DAX

    14,462.19
    +230.90 (+1.62%)
     
  • CAC 40

    6,515.75
    +105.17 (+1.64%)
     

Global Generic Oncology Sterile Injectable Market Report to 2027 - Size, Forecast, Insights and Competitive Landscape

·3-min read
Company Logo
Company Logo

Global Generic Oncology Sterile Injectable Market

Global Generic Oncology Sterile Injectable Market
Global Generic Oncology Sterile Injectable Market

Dublin, May 06, 2022 (GLOBE NEWSWIRE) -- The "Generic Oncology Sterile Injectable Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.

The global generic oncology sterile injectable market is expected to grow at a CAGR of around 11.3% during 2021-2027. This report on global generic oncology sterile injectable market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape.

The report presents a clear picture of the global generic oncology sterile injectable market by segmenting the market based on size, product type, disease indication, distribution channel, and region. Also, detailed profiles of companies operating in the generic oncology sterile injectable market are provided in this report.

Market Drivers

  • Increasing Launches of Drugs

  • Rising Prevalence of Cancer

Market Challenges

  • Stringent Rules and Regulations for Manufacturing

  • High Operational Costs

Historical & Forecast Period

  • Base Year: 2020

  • Historical Period: 2016-2019

  • Forecast Period: 2021-2027

Key Topics Covered:

1. Preface

2. Key Insights

3. Global Generic Oncology Sterile Injectable Market
3.1. Introduction
3.2. Market Drivers
3.3. Market Challenges

4. Global Generic Oncology Sterile Injectable Market Analysis
4.1. Market Portraiture
4.2. Market Size
4.3. Market Forecast
4.4. Impact of COVID-19

5. Global Generic Oncology Sterile Injectable Market by Product Type
5.1 Introduction
5.2 Chemotherapy
5.2.1 Alkylating Agents
5.2.2 Antimetabolites
5.2.3 Plant Alkaloids
5.2.4 Antitumor Antibiotics
5.2.5 Others
5.3 Monoclonal Antibodies
5.4 Cytokines
5.5 Peptide Hormones

6. Global Generic Oncology Sterile Injectable Market by Disease Indication
6.1 Introduction
6.2 Ovarian Cancer
6.3 Breast Cancer
6.4 Lung Cancer
6.5 Pancreatic Cancer
6.6 Others

7. Global Generic Oncology Sterile Injectable Market by Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies

8. Global Generic Oncology Sterile Injectable Market by Region
8.1 Introduction
8.2 Europe
8.2.1 Germany
8.2.2 United Kingdom
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Russia
8.2.7 Netherlands
8.2.8 Rest of the Europe
8.3 North America
8.3.1 United States
8.3.2 Canada
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 South Korea
8.4.5 Australia
8.4.6 Indonesia
8.4.7 Rest of the Asia Pacific
8.5 Latin America
8.5.1 Mexico
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 Turkey
8.6.3 Iran
8.6.4 United Arab Emirates
8.6.5 Rest of Middle East & Africa

9. SWOT Analysis

10. Porter's Five Forces

11. Market Value Chain Analysis

12. Competitive Landscape
12.1. Competitive Scenario
12.2. Company Profile
12.2.1. Baxter International Inc.
12.2.2. Biocon Ltd.
12.2.3. Eli Lilly & Company
12.2.4. Hikma Pharmaceuticals PLC
12.2.5. Mylan N.V.
12.2.6. Pfizer Inc.
12.2.7. Sandoz International GmbH
12.2.8. Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/g1eljf

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting